In our weekly expert view piece, British entrepreneur Jim Mellon, predicts future trends and patterns in the biopharmaceutical space.
Recently I spoke at BioTrinity 2016 in London, an industry conference for health care professionals, and probably the most important in the UK.
Prior to me speaking, George Freeman, the UK’s Minister for Life Sciences, made a politician's lengthy speech about how the government was committed to biotech, was “investing” in it, and was an advocate of its fundamental importance to the UK economy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze